Record-breaking 3D bioprinter could speed up drug development
Nanoengineers have developed a high-throughput bioprinter that 3D prints at record speed, potentially accelerating drug development.
List view / Grid view
Nanoengineers have developed a high-throughput bioprinter that 3D prints at record speed, potentially accelerating drug development.
Researchers have developed a new method that manipulates tiny water droplets in lab-on-chip applications for cell culturing and drug screening.
In this original report, find an in-depth analysis of AI and informatics within imaging, synthetic biology, drug screening and drug design. Featured interviews with experts from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
A novel synthetic “switch” has been developed that could hold the key to revolutionary smart insulin therapy for diabetic patients.
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
JDRF funds development of an insulin-producing implant to regulate blood glucose levels in type 1 diabetes patients.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Researchers at UT Southwestern have invented a novel microscopy method that could open new avenues of advanced microscopy.
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
Genome editing technologies have given investigators the power to unlock a variety of new applications and experimental approaches. While gene knockouts have been achievable for several years, successful gene knock-ins have remained elusive due to the low efficiency of homology-directed repair (HDR).
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).